Alzamend Neuro Reports Positive Pharmacodynamic Data from Phase II Clinical Trial of AL001

On April 7, 2026, Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, announced encouraging pharmacodynamic findings from its Phase II clinical trial of AL001, a novel treatment aimed at addressing neurological disorders including Alzheimer's disease, bipolar disorder type 1, major depressive disorder, and post-traumatic stress disorder. The trial was conducted at Massachusetts General Hospital, highlighting the potential of AL001 to reshape treatment paradigms in psychiatry.

The study utilized advanced brain magnetic resonance spectroscopy (MRS) to analyze changes in five critical brain metabolites across 18 regions in six healthy human subjects. Participants received two weeks of AL001, which is a blood bioequivalent and lithium-dose equivalent formulation, and results were compared to those from lithium carbonate, a standard treatment for bipolar disorder.

Preliminary findings indicated that while AL001 led to a downward trend in multiple brain chemicals, lithium carbonate caused these same chemicals to trend upward. This suggests that AL001 may interact with brain chemistry in a manner that is less disruptive to healthy brain tissue when compared to lithium carbonate. Such a distinction could offer a significant tolerability advantage for patients.

Both AL001 and lithium carbonate effectively reduced levels of myo-inositol, a key brain chemical associated with lithium's therapeutic effects. However, AL001 demonstrated a broader impact, affecting nearly twice as many brain regions (17 out of 18) as lithium carbonate (8 out of 18). This finding indicates that AL001 may deliver the benefits of lithium more extensively throughout the brain.

Another critical revelation was the stability of glutamate levels in healthy brain tissue following treatment with AL001. In contrast, lithium carbonate disrupted glutamate levels across all measured brain regions. Maintaining glutamate stability is crucial for long-term brain health, suggesting that AL001 could offer fewer cognitive side effects compared to traditional lithium treatments.

Stephan Jackman, Chief Executive Officer of Alzamend, commented on the findings, stating, "Lithium carbonate has been a cornerstone of psychiatric treatment for over 55 years, but its harsh side effect profile has always limited how widely and how long it can be used. These findings suggest AL001 may finally change that equation, delivering what lithium does best, without much of what makes it difficult to tolerate."

Following these initial results, Alzamend has outlined several hypotheses for further investigation in larger, adequately powered studies. These include:

AL001 represents a patented ionic cocrystal formulation of lithium combined with L-proline and salicylate. This innovative approach aims to deliver a therapeutic amount of lithium to the brain with reduced systemic exposure compared to traditional lithium carbonate. The goal is to provide a safer and better-tolerated therapy for patients suffering from Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

The study employed ultra-high field high-resolution magnetic resonance spectroscopic imaging (MRSI) to assess brain metabolite concentrations in healthy volunteers over a 14-day period. The research methodology was developed by Dr. Ovidiu C. Andronesi at Massachusetts General Hospital, underscoring the rigorous scientific approach behind these findings.

Alzamend Neuro's recent press release marks a significant milestone in the development of AL001 as a potential treatment option. By addressing the limitations of existing therapies like lithium carbonate, AL001 may offer new hope to millions of Americans living with psychiatric disorders. As the company seeks to confirm these promising findings in larger trials, the medical community and patients alike will be watching closely for future developments.